The business of bioanalysis: Expert panel addresses hot topics in industry
Filmed at the 11th WRIB (Los Angeles, CA, USA, 3-7 April 2017), the series covers conversation between Scott Fountain (Charles River Laboratories), Zamas Lam (QPS), Roger Hayes (MPI Research), Yan Zhang (Bristol-Myers Squibb), Ola Saad (Genentech) and Afshin Safavi (BioAgilytix). The speakers discuss how they, their organizations and their industries deal with issues such as: investment in new technologies; recruiting and retaining new talent; acquisitions and mergers, and how to encourage change and development within the bioanalysis community.
As the amount of work being outsourced in the industry increases, any issues surrounding outsourcing are becoming more prominent and urgent. The opportunity for so many representatives from different pharma and CRO backgrounds to talk openly about these issues is exceptionally rare, especially as outsourcing becomes more of a fundamental stage in drug discovery and development, making this panel discussion an important resource for the whole bioanalytical community
Published in three parts exclusively on Bioanalysis Zone, the first video in the series addresses the introduction of emerging technologies, in which the panelists discuss the timing of technology introduction and implications beyond financial investment. In subsequent videos, the panel goes on to share their perspectives on the acquisition of new bioanalytical talent, as well as retaining and training bioanalytical scientists. Mentorship and the development of 'soft-skills' are considered as the series progresses, before the impact of mergers, acquisitions and organic growth.
Sarah Mayes, Publisher of Bioanalysis Zone, commented: "We are delighted to be able to present these videos to the community in what is a rare opportunity for CROs and Pharma to have open conversations about issues affecting them in industry. There is a lot to learn from these panel discussions, and I hope the bioanalytical community enjoys watching them as much as we enjoyed filming them."
Bioanalysis Zone would also like to take this opportunity to thank the speakers, as well as the sponsors of this series, without whom the panel event would not be possible: BioAgilytix, Charles River, QPS and MPI Research.
The series of discussion videos is available to watch now at: http://www.bioanalysis-zone.com/2017/09/01/bioanalysis-zone-panel-discussion-bob2017/
Bioanalysis is a MEDLINE-indexed journal covering the latest scientific, technical and regulatory developments relevant to those working on the analysis of xenobiotics and biotics in biological matrices. This is, primarily, bioanalysts working in pharmaceutical research and development, clinical laboratories, clinical toxicologists, forensic toxicologists and sports doping analysts.
About Bioanalysis Zone
Since launching in 2011, Bioanalysis Zone has attracted over 7,500 active members from the global bioanalytical community, representing the pharmaceutical, biotech and CRO industries, along with academia and healthcare. Each month, thousands of members visit the site to read industry news, original research exclusive interviews and commentaries. Membership is completely free of charge. Sign up online at: http://www.bioanalysis-zone.com/register.
About Future Science Group
Founded in 2001, Future Science Group (FSG) is a progressive publisher focused on breakthrough medical, biotechnological and scientific research. FSG's portfolio includes two imprints, Future Science and Future Medicine. In addition to this core publishing business, FSG develops specialist eCommunities. Key titles and sites include Bioanalysis Zone, Epigenomics, Nanomedicine and the award-winning Regenerative Medicine. http://www.futuresciencegroup.com.
The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards. http://www.future-science-group.com.